TIDMHCM
Hutchison China Meditech Limited
06 December 2016
Press Release
Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor
HMPL-523 at the 2016 American Society of Hematology Annual
Meeting
London: Tuesday, December 6, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data
from a recent pre-clinical study, investigating the in vitro and in
vivo anti-tumor activities of novel Spleen Tyrosine Kinase ("Syk")
inhibitor, HMPL-523, was presented at the Annual Meeting of the
American Society of Hematology ("ASH"), being held in San Diego,
CA, USA from December 3 to December 6, 2016.
Syk, a non-receptor type of tyrosine kinase, plays a pivotal
role in the regulation of the B-cell receptor (BCR) signaling
pathway, which regulates proliferation, differentiation and
survival of B lymphocytes. The abnormal activation of BCR signaling
is closely related to transformation and development of B-cell
lymphoma.
Presentation HMPL-523, a Novel Syk Inhibitor, Showed
Title: Anti-Tumor Activities in Vitro and in
Vivo
Authors: Na Yang, Wei Deng, Qiaoling Sun, Junqing
Liang, Linfang Wang, Shiming Fan, Renxiang
Tang, Ying Yu, Junen Sun, Feng Zhou,
Guangxiu Dai, Weiguo Qing, Weiguo Su
and Yongxin Ren
Abstract
No: 3970
Session: 605. Molecular Pharmacology, Drug Resistance-Lymphoid
and Other Diseases
Date & Time: Monday, December 5, 2016, 6:00PM - 8:00PM
(PST)
The presentation is available at
www.chi-med.com/wp-content/uploads/2016/12/pre161206_523ash.pdf.
Potent anti-tumor activity and combination synergy with other
therapies
In vitro in B-cell lymphoma cell lines with Syk/BCR
dysregulation, HMPL-523 was found to block phosphorylation of
B-cell linker protein as well as inhibit cell viability by
inhibiting cell survival and increasing apoptotic rate. HMPL-523
also showed synergistic anti-tumor activity on human diffused large
B-cell lymphoma cells, in combination with other drugs such as
Phosphoinositide-3-Kinase inhibitors, B-cell lymphoma 2 family
inhibitors, or chemotherapies. Potent anti-tumor activity was also
demonstrated in nude mice bearing B-cell lymphoma xenograft tumors
with Syk/BCR dysregulation.
Clinical development in oncology and immunology
In hematological malignancies, HMPL-523 is currently being
studied in a Phase I dose escalation study, which was initiated in
Australia in January 2016 and is expected to complete in the first
half of 2017. This study is in patients with relapsed and/or
refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic
leukemia for whom there is no standard therapy.
HMPL-523 is also being studied in immunological indications.
Clinical data for HMPL-523 in a Phase I dose-escalating study in
healthy volunteers in Australia was recently presented at the 2016
Annual Meeting of the American College of Rheumatology/Association
of Rheumatology Health Professionals, which was held in November
2016. The detailed poster presentation can be viewed at
www.chi-med.com/wp-content/uploads/2016/11/pre1611141.png. The
Company plans to initiate a Phase II study in the U.S. in 2017.
About the ASH Annual Meeting
The ASH annual meeting, a scientific conference focused on
malignant and non-malignant hematology, brings together more than
20,000 hematology professionals from around the world. The meeting
provides an educational experience, with thousands of scientific
abstracts highlighting the latest research in the field available
for review, as well as the opportunity to network with a global
community of professionals from every subspecialty.
About B-cell signaling
The BCR signaling pathway regulates proliferation,
differentiation and survival of B lymphocytes, a major cellular
component of the immune system. The abnormal activation of BCR
signaling is closely related to transformation and development of
hematological cancers (i.e. B-cell malignancies) including lymphoma
and leukemia, as well as autoimmune diseases, such as rheumatoid
arthritis. Targeted B-cell receptor signaling therapies, including
monoclonal antibodies and small molecules, have been proven to be
clinically effective for the treatment of B-cell malignancies,
leading to scientific and commercial success.
Syk is a key protein involved in the B-cell signaling
pathway.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
HMPL-523, plans to initiate clinical studies for HMPL-523, its
expectations as to whether such studies would meet their primary or
secondary endpoints, and its expectations as to the timing of the
completion and the release of results from such studies.
Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions
regarding enrollment rates, timing and availability of subjects
meeting a study's inclusion and exclusion criteria, changes to
clinical protocols or regulatory requirements, unexpected adverse
events or safety issues, the ability of drug candidate HMPL-523 to
meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions, to gain commercial
acceptance after obtaining regulatory approval, the potential
market of HMPL-523 for a targeted indication and the sufficiency of
funding. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. For further discussion of these
and other risks, see Chi-Med's filings with the U.S. Securities and
Exchange Commission and on AIM. Chi-Med undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSSSMMFMSELE
(END) Dow Jones Newswires
December 06, 2016 02:01 ET (07:01 GMT)